Sir, I had a question with respect to the base business ex Cenexi. Now if we see our base business ex Cenexi has been flat for past 5, 6 quarters. Now listening a year back, we had guided to a mid-teen’ kind of growth on the base business as well. But given the muted trends which we are seeing on the base business, apart from the ramp-up, which we expect in second half because of a couple of new launches like dalbavancin, can you provide some outlook in terms of how the base business growth would be going into '27, '28. So that's my first question?
Sure, sir. So this mid-teen growth guidance, which we have for '26, obviously, there is a currency benefit of Cenexi sitting in there. So Cenexi in first half of this year has grown 30% in INR terms. But if I look at the constant currency growth for Cenexi, that's around 10%. So this year again, has been muted if you ex out the currency benefits. So yes, some better visibility, clarity in terms of what would help us to achieve this mid-teen kind of a growth going forward would be helpful?